Benzinga | Oct 27, 2020 04:08PM EDT

Ultragenyx Pharmaceutical Q3 EPS $(1.13) Beats $(1.27) Estimate, Sales $81.47M Beat $53.89M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.27) by 11.02 percent. This is a 42.35 percent increase over losses of $(1.96) per share from the same period last year. The company reported quarterly sales of $81.47 million which beat the analyst consensus estimate of $53.89 million by 51.18 percent. This is a 215.78 percent increase over sales of $25.80 million the same period last year.